Stay updated on Adagrasib in KRAS G12C+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Adagrasib in KRAS G12C+ Solid Tumors Clinical Trial page.

Latest updates to the Adagrasib in KRAS G12C+ Solid Tumors Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange Detected- Added a government funding operating-status notice and updated operating details for NIH Clinical Center (high importance). - Updated version from v3.1.0 to v3.2.0 (moderate importance).SummaryDifference13%
- Check18 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.3%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedUpdated the page to Revision: v3.0.2, replacing the previous v3.0.1. The 'Back to Top' control was removed, a minor UI change.SummaryDifference0.8%
- Check39 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.8%
- Check46 days agoChange DetectedThe web page has been updated to include a new facility name and location, specifically mentioning Bristol-Myers Squibb, while removing references to Mirati Therapeutics Inc. and various location details.SummaryDifference10%
- Check61 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.3%
Stay in the know with updates to Adagrasib in KRAS G12C+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib in KRAS G12C+ Solid Tumors Clinical Trial page.